Scientific Program Committee

CROI 2008 Session 20
i Tuesday, 8:30-9 am; Auditorium
Session 18–Plenary CME
Challenges in Pediatric and Adolescent HIV Care
65
Lynne Mofenson
Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD,
US
Objectives: This session is directed to clinicians and scientists interested
in treatment and management of HIV-infected children and adolescents in
resource-rich and resource-limited settings. It is assumed that participants
are familiar with interventions to prevent mother-to-child HIV transmission,
the principles of ART, and the clinical course of pediatric HIV infection.
At the completion of the session, participants will be knowledgeable about
differences between pediatric and adult HIV infection, factors associated with
response to ART and choice of antiretroviral drugs in children, including
maternal antiretroviral drug exposure, long-term complications of ART in
children, issues related to the aging of infected children into adulthood, and
barriers to treatment of children in resource-limited countries.
j Tuesday, 9-9:30 am; Auditorium
Session 19–Plenary CME
Natural Enhancers and Inhibitors of HIV Infection
66
J Munch 1 , L Standker 2,3 , WG Forssmann 2,3 , and Frank Kirchhoff* 1
1 Univ Clin of Ulm, Germany; 2 VIRO Pharma GmbH & Co,
Hannover, Germany; and 3 Hannover Med Sch, Ctr of Pharma,
Hannover, Germany
Objectives: This session is directed to clinicians and scientists interested in
sexual transmission of HIV/AIDS. It is assumed that participants are familiar
with the basic aspects of HIV entry into target cells. At the completion of
the session, participants will be knowledgeable about the presence of factors
enhancing the infectiousness of HIV in semen, the mechanisms underlying the
enhancement of HIV infection, and the potential relevance of amyloid fibrils
in the transmission of HIV and other viruses.
k Tuesday, 10-11:30 am; Room 302-304
CME
Session 20–Oral Abstracts
Insights into Neuropathogenesis
Moderators:
Paola Cinque, San Raffaele Sci Inst, Milan, Italy
David Clifford, Washington Univ Sch of Med, St Louis, MO, US
10:00 67 Reducing the Prevalence of Primary HIV Brain
Pathology by Antiretrovirals
Ian Everall* 1 , F Vada1 , S Letendre1 , D Lazzaretto1 , B Gelman2 ,
S Morgello3 , E Singer4 , R Ellis1 , E Masliah1 , I Grant1 , and
Natl NeuroAIDS Tissue Consortium and the UCSD HIV
Neurobehavioral Res Ctr
1 2 Univ of California, San Diego, US; Univ of Texas Med Branch,
Galveston, US; 3Mt Sinai Med Ctr, New York, NY, US; and 4Univ of
California, Los Angeles, US
10:15 68 Low-grade Immune Restoration Disease May Limit
Recovery from HIV-associated Neurocognitive
Impairment
Scott Letendre*, R Ellis, L Cysique, M Cherner, S Gibson,
R Heaton, A McCutchan, and the HNRC Group
Univ of California, San Diego, US
10:30 69 Elevated Plasma Endotoxin Associated with Monocyte
Activation and Reduced BDNF in AIDS Patients with
Dementia
Petronela Ancuta* 1 , K Kunstman2 , EY Kim2 , P Autissier3 ,
M Mefford4 , D Stone5 , S Wolinsky2 , and D Gabuzda4 1 2 Univ of Montreal, Canada; Northwestern Univ, Chicago, IL, US;
3 4 Beth Israel Deaconess Med Ctr, Boston, MA, US; Dana-Farber
Cancer Inst, Boston, MA, US; and 5Lemuel Shattuck Hosp, Jamaica
Plain, MA, US
10:45 70 HIV Infection of the Cerebrospinal Fluid of Elite
Controllers
John Probasco*, S Deeks, E Lee, R Hoh, T Liegler, R Price, and
S Spudich
Univ of California, San Francisco, US
11:00 71 Influence of Immunological, Virological, and
Radiological Determinants in the Clinical
Outcome of Patients with Progressive Multifocal
Leukoencephalopathy
A Marzocchetti1 , T Tompkins1 , D Clifford2 , R Gandhi3 , S Kesai4 ,
J Berger5 , D Simpson6 , A DeLuca7 , and Igor Koralnik* 1
1Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA,
US; 2Washington Univ Sch of Med, Seattle, US; 3Massachusetts Gen
Hosp, Harvard Med Sch, Boston, US; 4Brigham and Women’s Hosp,
Boston, MA, US; 5Univ of Kentucky Coll of Med, US; 6Mt Sinai Med
Ctr, New York, NY, US; and 7Catholic Univ, Rome, Italy
11:15 72 Natural Genetic Resistance to Lentiviral CNS Disease:
A Neuroprotective MHC Class I Allele in SIV-infected
Macaques
Joseph Mankowski* 1 , S Queen1 , C Fernandez2 , P Tarwater3 ,
J Karper1 , R Adams1 , and S Kent2 1 2 Johns Hopkins Univ, Baltimore, MD, US; Univ of Melbourne,
Australia; and 3Univ of Texas Hlth Sci Ctr at Houston, Sch of Publ
Hlth, El Paso, US
Program 11
Tuesday
February 5 Sessions